Notice: This company has been marked as potentially delisted and may not be actively trading. DICE Therapeutics (DICE) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH ReadoutNovember 6, 2024 | seekingalpha.comEli Lilly and Company (NYSE:LLY) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comBuy, Sell, Or Hold LLY Stock At $850?October 31, 2024 | forbes.comWe tried Factor’s prepared meal delivery service for over three years: Full reviewOctober 12, 2024 | msn.comEverything You Need To Know About Zelda: Echoes Of WisdomSeptember 26, 2024 | msn.comSteven Schumacher joins Stoke City list of doom as ruthless Jon Walters takes responsibilitySeptember 16, 2024 | msn.comEli Lilly and Company (LLY): Jim Cramer's Go-To Stock For SuccessAugust 31, 2024 | msn.comLilly beefs up bowel disease drug portfolio with $3.2 billion Morphic dealAugust 8, 2024 | msn.comIs Eli Lilly Stock Headed Toward $1300 Levels?July 26, 2024 | forbes.com"It's just a disgrace": Port Richmond residents demand city fix multiple craters on Aramingo AvenueJuly 25, 2024 | yahoo.comQ3 2024 Resmed Inc Earnings CallApril 26, 2024 | finance.yahoo.comMinishoot' Adventures Hits Steam: A Bullet-Hell Bonanza with a Zelda TwistApril 3, 2024 | msn.comVoyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver EasierMarch 8, 2024 | seekingalpha.comStoke City player ratings vs Cardiff as Potters sink into relegation zoneFebruary 24, 2024 | msn.comAbercrombie Announces Official Partnership With McLaren Racing, Features Race Car in Fifth Avenue StoreJanuary 31, 2024 | es-us.finanzas.yahoo.com15 Best Acne Treatment Products For Teens in 2024January 30, 2024 | msn.comStar Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial OfficerJanuary 3, 2024 | finance.yahoo.comAltamira Therapeutics stock rises after it regains compliance with NasdaqDecember 30, 2023 | msn.comCan a Big Pharma Ever Be Worth $1 Trillion?November 29, 2023 | msn.comQ3 2023 Eli Lilly and Co Earnings CallNovember 4, 2023 | uk.finance.yahoo.comEli Lilly to buy Dice Therapeutics for $2.4 billionOctober 25, 2023 | investing.comImmetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune DiseasesOctober 12, 2023 | es-us.finanzas.yahoo.comPoint Biopharma shares storm ahead 84% after Eli Lily's $1.4bn bidOctober 3, 2023 | proactiveinvestors.comIs Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?September 29, 2023 | msn.comWells Fargo Sticks to Their Hold Rating for Incyte (INCY)September 11, 2023 | markets.businessinsider.comWhy These 3 Large Caps Are Bucking the August Slump (DICE)The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023.August 22, 2023 | marketbeat.comY Intercept Hong Kong Ltd Takes Position in DICE Therapeutics, Inc. (NASDAQ:DICE)Y Intercept Hong Kong Ltd bought a new position in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 7,098 shares of the company's stock, valueAugust 21, 2023 | marketbeat.comWhat 9 Analyst Ratings Have To Say About DICE TherapeuticsAugust 9, 2023 | markets.businessinsider.comEli Lilly and Company: Lilly Completes Acquisition of DICE TherapeuticsAugust 9, 2023 | finanznachrichten.deHC Wainwright & Co. Reiterates DICE Therapeutics (DICE) Neutral RecommendationAugust 9, 2023 | msn.comLilly Completes Acquisition of DICE TherapeuticsAugust 9, 2023 | finance.yahoo.comVersor Investments LP Invests $286,000 in DICE Therapeutics, Inc. (NASDAQ:DICE)Versor Investments LP purchased a new position in DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the company's stock, valued at approximatAugust 9, 2023 | marketbeat.comTrading was temporarily halted for "DICE" at 07:08 PM with a stated reason of "News pending."August 9, 2023 | marketbeat.comEli Lilly and Company: Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsAugust 8, 2023 | finanznachrichten.deLilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline AdvancementsAugust 8, 2023 | markets.businessinsider.comDICE Therapeutics, Inc. (NASDAQ:DICE) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC cut its stake in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) by 41.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,713 shares of the company's stock afterAugust 8, 2023 | marketbeat.comJump Financial LLC Has $496,000 Stock Holdings in DICE Therapeutics, Inc. (NASDAQ:DICE)Jump Financial LLC lessened its stake in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) by 41.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,311 shares of the company's stock afteAugust 7, 2023 | marketbeat.comLilly Extends Tender Offer To Acquire DICEJuly 25, 2023 | markets.businessinsider.comLilly Announces Extension of Tender Offer to Acquire DICEJuly 25, 2023 | finance.yahoo.comDrugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts sayJuly 12, 2023 | msn.comDICE Therapeutics (DICE) Price Target Decreased by 19.70% to 50.21July 6, 2023 | msn.comMergers Are Down, but These 2 Sectors Are BoomingJune 27, 2023 | finance.yahoo.comShort Volatility Alert: Dice TherapeuticsJune 26, 2023 | benzinga.comNeedham Downgrades DICE Therapeutics (DICE)June 26, 2023 | msn.comNeedham Downgrades DICE Therapeutics to HoldJune 26, 2023 | benzinga.comNorthpond Ventures Gp, Llc Sells 2,492,871 Shares of DICE Therapeutics, Inc. (NASDAQ:DICE) StockDICE Therapeutics, Inc. (NASDAQ:DICE - Get Rating) major shareholder Northpond Ventures Gp, Llc sold 2,492,871 shares of the firm's stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $46.50, for a total value of $115,918,501.50. Following the completion of the sale, the insider now directly owns 166,293 shares in the company, valued at approximately $7,732,624.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.June 23, 2023 | marketbeat.comBrokers Issue Forecasts for DICE Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:DICE)DICE Therapeutics, Inc. (NASDAQ:DICE - Get Rating) - Stock analysts at HC Wainwright lowered their FY2027 earnings estimates for DICE Therapeutics in a report issued on Wednesday, June 21st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($5.82) fJune 23, 2023 | marketbeat.comDice Therapeutics (DICE) Receives a New Rating from a Top AnalystJune 21, 2023 | markets.businessinsider.comRed Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover (DICE)The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer.June 21, 2023 | marketbeat.comCantor Fitzgerald Downgrades DICE Therapeutics (DICE)June 21, 2023 | msn.com Get DICE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DICE and its competitors with MarketBeat's FREE daily newsletter. Email Address I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. DICE Media Mentions By Week DICE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DICE News Sentiment▼0.000.60▲Average Medical News Sentiment DICE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DICE Articles This Week▼00▲DICE Articles Average Week Get DICE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DICE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LianBio News PHAXIAM Therapeutics News Alpha Tau Medical News BriaCell Therapeutics News Fortress Biotech News GeoVax Labs News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DICE) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DICE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DICE Stock Alerts